Maternus-Kliniken Aktiengesellschaft Logo

Maternus-Kliniken Aktiengesellschaft

MAK.DE

(1.8)
Stock Price

1,55 EUR

-5.99% ROA

16.25% ROE

-4.42x PER

Market Cap.

37.326.600,00 EUR

-197.62% DER

0% Yield

-10.98% NPM

Maternus-Kliniken Aktiengesellschaft Stock Analysis

Maternus-Kliniken Aktiengesellschaft Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Maternus-Kliniken Aktiengesellschaft Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (41.93%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-1.57x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a minimal amount of debt (-433%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

5 ROA

The stock's ROA (-10.05%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-43) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Maternus-Kliniken Aktiengesellschaft Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Maternus-Kliniken Aktiengesellschaft Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Maternus-Kliniken Aktiengesellschaft Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Maternus-Kliniken Aktiengesellschaft Revenue
Year Revenue Growth
2007 106.405.000
2008 109.812.000 3.1%
2009 112.797.000 2.65%
2010 111.811.000 -0.88%
2011 110.904.000 -0.82%
2012 113.942.000 2.67%
2013 113.566.000 -0.33%
2014 122.041.000 6.94%
2015 123.269.000 1%
2016 124.040.000 0.62%
2017 127.143.000 2.44%
2018 124.278.000 -2.31%
2019 124.430.000 0.12%
2020 114.299.000 -8.86%
2021 111.437.000 -2.57%
2022 106.697.000 -4.44%
2023 103.150.000 -3.44%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Maternus-Kliniken Aktiengesellschaft Research and Development Expenses
Year Research and Development Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Maternus-Kliniken Aktiengesellschaft General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 5.669.000 100%
2013 5.776.000 1.85%
2014 4.797.000 -20.41%
2015 5.019.000 4.42%
2016 4.159.000 -20.68%
2017 4.270.000 2.6%
2018 3.272.000 -30.5%
2019 3.662.000 10.65%
2020 3.032.000 -20.78%
2021 3.064.000 1.04%
2022 2.962.000 -3.44%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Maternus-Kliniken Aktiengesellschaft EBITDA
Year EBITDA Growth
2007 9.051.000
2008 10.989.000 17.64%
2009 11.001.000 0.11%
2010 10.972.000 -0.26%
2011 8.957.000 -22.5%
2012 2.942.000 -204.45%
2013 -299.000 1083.95%
2014 37.671.000 100.79%
2015 13.329.000 -182.62%
2016 10.990.000 -21.28%
2017 11.386.000 3.48%
2018 8.631.000 -31.92%
2019 7.300.000 -18.23%
2020 11.044.000 33.9%
2021 15.163.000 27.16%
2022 3.172.000 -378.03%
2023 -4.119.000 177.01%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Maternus-Kliniken Aktiengesellschaft Gross Profit
Year Gross Profit Growth
2007 85.722.000
2008 87.964.000 2.55%
2009 91.426.000 3.79%
2010 91.404.000 -0.02%
2011 91.207.000 -0.22%
2012 96.079.000 5.07%
2013 93.189.000 -3.1%
2014 99.960.000 6.77%
2015 102.513.000 2.49%
2016 103.030.000 0.5%
2017 105.374.000 2.22%
2018 102.853.000 -2.45%
2019 102.861.000 0.01%
2020 97.699.000 -5.28%
2021 97.516.000 -0.19%
2022 86.979.000 -12.11%
2023 11.576.000 -651.37%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Maternus-Kliniken Aktiengesellschaft Net Profit
Year Net Profit Growth
2007 -4.277.000
2008 -2.742.000 -55.98%
2009 886.000 409.48%
2010 1.979.000 55.23%
2011 -1.888.000 204.82%
2012 -8.599.000 78.04%
2013 -12.725.000 32.42%
2014 26.844.000 147.4%
2015 2.358.000 -1038.42%
2016 1.104.000 -113.59%
2017 -1.456.000 175.82%
2018 -1.575.000 7.56%
2019 -10.256.000 84.64%
2020 -9.622.000 -6.59%
2021 -2.485.000 -287.2%
2022 -14.077.000 82.35%
2023 -10.078.000 -39.68%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Maternus-Kliniken Aktiengesellschaft Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 -1 0%
2014 1 100%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 -1 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Maternus-Kliniken Aktiengesellschaft Free Cashflow
Year Free Cashflow Growth
2007 3.025.000
2008 -5.587.000 154.14%
2009 1.645.000 439.64%
2010 -46.000 3676.09%
2011 2.318.000 101.98%
2012 1.707.000 -35.79%
2013 2.480.000 31.17%
2014 10.624.000 76.66%
2015 -5.184.000 304.94%
2016 7.094.000 173.08%
2017 5.925.000 -19.73%
2018 5.287.000 -12.07%
2019 15.069.000 64.91%
2020 11.431.000 -31.83%
2021 15.319.000 25.38%
2022 2.326.000 -558.6%
2023 1.413.500 -64.56%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Maternus-Kliniken Aktiengesellschaft Operating Cashflow
Year Operating Cashflow Growth
2007 3.802.000
2008 -5.103.000 174.51%
2009 3.228.000 258.09%
2010 1.853.000 -74.2%
2011 5.546.000 66.59%
2012 4.382.000 -26.56%
2013 3.068.000 -42.83%
2014 11.303.000 72.86%
2015 -2.906.000 488.95%
2016 7.902.000 136.78%
2017 6.922.000 -14.16%
2018 6.234.000 -11.04%
2019 16.030.000 61.11%
2020 12.167.000 -31.75%
2021 17.244.000 29.44%
2022 4.329.000 -298.34%
2023 3.021.000 -43.3%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Maternus-Kliniken Aktiengesellschaft Capital Expenditure
Year Capital Expenditure Growth
2007 777.000
2008 484.000 -60.54%
2009 1.583.000 69.43%
2010 1.899.000 16.64%
2011 3.228.000 41.17%
2012 2.675.000 -20.67%
2013 588.000 -354.93%
2014 679.000 13.4%
2015 2.278.000 70.19%
2016 808.000 -181.93%
2017 997.000 18.96%
2018 947.000 -5.28%
2019 961.000 1.46%
2020 736.000 -30.57%
2021 1.925.000 61.77%
2022 2.003.000 3.89%
2023 1.607.500 -24.6%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Maternus-Kliniken Aktiengesellschaft Equity
Year Equity Growth
2007 -9.153.000
2008 -11.960.000 23.47%
2009 -11.077.000 -7.97%
2010 -9.393.000 -17.93%
2011 -11.242.000 16.45%
2012 13.953.000 180.57%
2013 3.826.000 -264.69%
2014 -2.741.000 239.58%
2015 -262.000 -946.18%
2016 847.000 130.93%
2017 -847.000 200%
2018 -2.549.000 66.77%
2019 -11.299.000 77.44%
2020 -18.700.000 39.58%
2021 -23.845.000 21.58%
2022 -37.550.000 36.5%
2023 -52.115.000 27.95%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Maternus-Kliniken Aktiengesellschaft Assets
Year Assets Growth
2007 130.540.000
2008 132.158.000 1.22%
2009 128.591.000 -2.77%
2010 131.294.000 2.06%
2011 129.486.000 -1.4%
2012 131.520.000 1.55%
2013 121.864.000 -7.92%
2014 122.469.000 0.49%
2015 119.247.000 -2.7%
2016 111.001.000 -7.43%
2017 108.484.000 -2.32%
2018 127.905.000 15.18%
2019 165.441.000 22.69%
2020 178.627.000 7.38%
2021 165.414.000 -7.99%
2022 153.400.000 -7.83%
2023 154.379.000 0.63%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Maternus-Kliniken Aktiengesellschaft Liabilities
Year Liabilities Growth
2007 139.693.000
2008 144.118.000 3.07%
2009 139.668.000 -3.19%
2010 140.687.000 0.72%
2011 140.728.000 0.03%
2012 151.183.000 6.92%
2013 154.124.000 1.91%
2014 128.254.000 -20.17%
2015 122.655.000 -4.56%
2016 113.349.000 -8.21%
2017 112.303.000 -0.93%
2018 133.330.000 15.77%
2019 181.279.000 26.45%
2020 204.034.000 11.15%
2021 193.261.000 -5.57%
2022 192.699.000 -0.29%
2023 206.494.000 6.68%

Maternus-Kliniken Aktiengesellschaft Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.67
Net Income per Share
-0.4
Price to Earning Ratio
-4.42x
Price To Sales Ratio
0.48x
POCF Ratio
-42.17
PFCF Ratio
-7.7
Price to Book Ratio
-0.7
EV to Sales
1.86
EV Over EBITDA
-219.81
EV to Operating CashFlow
-161.41
EV to FreeCashFlow
-29.49
Earnings Yield
-0.23
FreeCashFlow Yield
-0.13
Market Cap
0,04 Bil.
Enterprise Value
0,14 Bil.
Graham Number
4.82
Graham NetNet
-9.42

Income Statement Metrics

Net Income per Share
-0.4
Income Quality
0.06
ROE
0.16
Return On Assets
-0.05
Return On Capital Employed
-0.06
Net Income per EBT
1.2
EBT Per Ebit
1.43
Ebit per Revenue
-0.06
Effective Tax Rate
-0.22

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.38
Operating Profit Margin
-0.06
Pretax Profit Margin
-0.09
Net Profit Margin
-0.11

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.04
Free CashFlow per Share
-0.23
Capex to Operating CashFlow
-4.47
Capex to Revenue
0.05
Capex to Depreciation
0.41
Return on Invested Capital
-0.12
Return on Tangible Assets
-0.06
Days Sales Outstanding
44.28
Days Payables Outstanding
40.07
Days of Inventory on Hand
4.46
Receivables Turnover
8.24
Payables Turnover
9.11
Inventory Turnover
81.78
Capex per Share
0.19

Balance Sheet

Cash per Share
0,07
Book Value per Share
-2,48
Tangible Book Value per Share
-3.11
Shareholders Equity per Share
-2.56
Interest Debt per Share
5.36
Debt to Equity
-1.98
Debt to Assets
0.69
Net Debt to EBITDA
-162.44
Current Ratio
0.3
Tangible Asset Value
-0,07 Bil.
Net Current Asset Value
-0,18 Bil.
Invested Capital
71034000
Working Capital
-0,05 Bil.
Intangibles to Total Assets
0.09
Average Receivables
0,01 Bil.
Average Payables
0,01 Bil.
Average Inventory
586000
Debt to Market Cap
2.85

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Maternus-Kliniken Aktiengesellschaft Dividends
Year Dividends Growth
2000 0

Maternus-Kliniken Aktiengesellschaft Profile

About Maternus-Kliniken Aktiengesellschaft

Maternus-Kliniken Aktiengesellschaft operates retirement and nursing homes, rehabilitation clinics, and various service companies that operate in the field of geriatric care and rehabilitation medicine. The company also provides emergency call, assisted living, rehabilitation, and follow-up treatment services, as well as domestic, inpatient, short term, and handicapped care services. It operates approximately 23 facilities in Germany. The company was founded in 1877 and is headquartered in Berlin, Germany.

CEO
Mr. Mario Augusto Ruano Wohler
Employee
1.452
Address
FranzOesische Strasse 53 - 55
Berlin, 10117

Maternus-Kliniken Aktiengesellschaft Executives & BODs

Maternus-Kliniken Aktiengesellschaft Executives & BODs
# Name Age
1 Mr. Mario Augusto Ruano Wohlers
Member of Board of Management
70

Maternus-Kliniken Aktiengesellschaft Competitors